Re the Pharmac proposal talked about on this, I made a submission on that and today I got back the response to submitters report.
It sounds good for genotype 1 but not until after October at least while they train doctors and pharmacists. serious cases referred through clinics until then and no details about numbers or thresholds.
I am going to ask some more questions, but I am fairly pleased that my easily recognisable submission, which was a four page rant, has been nicely summarised as:
"One respondent was unsupportive of
the Gilead (Harvoni) proposal for
clinical, ethical and fiscal reasons.
The respondent considered the supplier’s behaviour has been
profiteering and that, in letting
patients become cirrhotic before
treatment, they create incurring
ongoing costs to the health system
" Pharmac response: Noted.
So that gets spread around nicely in the public document. Doesn't achieve anything but I like Gilead, behaviour and profiteering appearing together for submitters to read.
Genotype 3 30 years, 2x treatment interferon/ribavirin non responder. Cirrhosis 17 years. Fibroscan, decompensating, 40 down to 22 by 29/3/16- now down to 6.5, normal, no cirrhosis. Started Buyers Club Sof/Dac 14 Nov 15. SVR 12 29/0716